Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Isotechnika Pharma Inc IPHAF

GREY:IPHAF - Post Discussion

Isotechnika Pharma Inc > ISA , DEADBEAT debtor.......CHEQUE IN THE MAIL?
View:
Post by ISAloser247 on Sep 12, 2012 10:13am

ISA , DEADBEAT debtor.......CHEQUE IN THE MAIL?

....according to the revised agreement with Paladin Labs, January 30, 2012,    for the previously ordered batches of API ( voclosporin ), ISA had to pay installments .  The second payment was to be made by July 31, 2012.  IT WAS NOT MADE!  as a result final payment ------due and payable     with a 6% charge on top.  Third and final installment was due September 30, 2012.  Total balance, minus interest is $ 1, 698, 000--which ISA obviously does not have and Dr. Foster can not find in between the seat cushions.  Lux did not pay on THEIR "Agreements", disputing amounts, timing etc., JUST A COMPLETE CLUSTERF**K!  it is always the same with Dr. Foster , one F**K UP after another.....
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities